\\ Probiotic Technology 

Ganeden Biotech is a science-driven organization dedicated to meeting the probiotic needs of markets that have otherwise been unmet by traditional solutions. Ganeden Labs, the company’s licensing and development division, makes proprietary, patented probiotic technology available for use in innovative products in a broad range of applications including functional probiotic foods and beverages, topical applications and feed additives for use in animal health and livestock production.

Ganeden’s probiotic bacteria, specifically its core strain GanedenBC30®, are self-affirmed GRAS and very effective in surviving most manufacturing proccesses. It has been shown to support the digestive system and immune system.

The company’s state-of-the-art research and development facility, located in Miami, Florida, is one of the most advanced probiotic technological research laboratories in the world. Guided by company founder and Chief Scientific Officer Sean Farmer, a leading microbiologist and fermentation specialist, Ganeden’s R&D; organization has capabilities ranging from strain selection and genetic identification to product development support and stability testing. By working in partnership with licensees, Ganeden’s research team works to ensure the most stable, efficacious probiotic products available.

Ongoing research and clinical studies are integral to the mission of Ganeden Labs. Leading members of the scientific and medical communities support the company’s probiotic technology and are working to advance science and discover new and useful applications of Ganeden’s unique strains.

Published Studies

Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-Induced colitis following vancomycin withdrawal in mice
Gut Pathogens, 2012, 4:13
Leo R Fitzpatrick, Jeffrey S Small, Wallace H Greene, Kelly D Karpa, Sean Farmer and David Keller

A review of probiotics studies in HIV research suggests improved immunological presentation and preservation of viral host restrictive factors of TH17 in HIV patients
Retrovirology, 2012, 9(Suppl 1):P22
M Selbovitz, Keller, Miller, Moore, Farmer and Bray

Probiotic metabolites from Bacillus coagulans GanedenBC30® support maturation of antigen-presenting cells in vitro
World Journal of Gastroenterology, 2012, 18(16): 1875–1883.
Kathleen F Benson, Kimberlee A Redman, Steve G Carter, David Keller, Sean Farmer, John R Endres and Gitte S Jensen

Impact of GanedenBC30 (Bacillus coagulans GBI-30, 6086) on population dynamics of the human gut microbiota in a continuous culture fermentation system
International Journal of Probiotics and Prebiotics, 2011, 6 (1): 65-72.
Harue Honda1, Lesley Hoyles1, Glenn R. Gibson2, Sean Farmer3, David Keller3 and Anne L. McCartney1

Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice
Gut Pathogens, 2011, 3:16
Leo R Fitzpatrick1, Jeffrey S Small1, Wallace H Greene2, Kelly D Karpa1 and David Keller3

One-Year Chronic Oral Toxicity With Combined Reproduction Toxicity Study Of A Novel Probiotic, Bacillus Coagulans, As A Food Ingredient
Food and Chemical Toxicology Article in Press
J.R. Endresa, I. Qureshia, T. Farberb, J. Hauswirthc, G. Hirkad, I. Pasicsd, A.G. Schaussa

Use Of A Continuous Culture Fermentation System To Investigate The Effect Of GanedenBC30 Bacillus Coagulans GBI-30, 6086) Supplementation On Pathogen Survival In The Human Gut Microbiota
Anarobe 2011, 17 (1): 36-42
H. Hondaa, G.R. Gibsona, S. Farmerb, D. Kellerb, A.L. McCartneya

Bacillus Coagulans As A Probiotic.
Food Science & Technology Bulletin: Functional Foods 2010, 7 (7): 103-109
D. Keller1, S. Farmer1, A.L. McCartney2, G. Gibson2

A Controlled Clinical Trial To Evaluate The Effect of GanedenBC30 On Imunological Markers.
Methods and Findings in Experimental and Clinical Pharmacology 2010, 32(2): 129-132
M. Kimmel1, D. Keller2, S. Farmer2, D.E. Warrino3

GanedenBC30TM Cell Wall And Metabolites: Anti–inflammatory And Immune Modulating Effects In vitro.
BMC Immunology 2010, 11:15
Gitte S Jensen1, Kathleen F Benson1, Steve G Carter1, John R Endres2*

Bacillus coagulans : A Viable Adjunct Therapy For Relieving Symptoms Of Rheumatoid Arthritis According To A Randomized, Controlled Trial.
BMC Complementary and Alternative Medicine 2010, 10:1
David R Mandel1*, Katy Eichas2, Judith Holmes1

Effects Of A Proprietary Bacillus Coagulans Preparation On Symptoms Of Diarrhea–Predominant Irritable Bowel Syndrome.
Methods Find Exp Clin Pharmacol 2009; 31(10): 655–659
B.J. Dolin

Survival And Metabolic Activity Of The GanedenBC30Strain Of Bacillus Coagulans In A Dynamic In Vitro Model Of The Stomach And Small Intestine
Beneficial Microbes, 2010; 1(1): 31–36
A.J.H Maathuis1, D. Keller2, S. Farmer2

A Prospective, Randomized, Double–blind, Placebo–controlled Parallel–group Dual Site Trial To Evaluate The Effects Of A Bacillus Coagulans–based Product On Functional Intestinal Gas Symptoms
BMC Gastroenterology, 2009, 9:85
Douglas S Kalman*1, Howard I Schwartz1, Patricia Alvarez2, Samantha Feldman1, John C Pezzullo1 and Diane R Krieger1

Bacillus Coagulans Significantly Improved Abdominal Pain And Bloating In Patients With IBS
Postgraduate Medicine, 2009; 121(2): 119–124
Larysa Hun

A Patented Strain Of Bacillus Coagulans Increased Immune Response To Viral Challenge
Postgraduate Medicine, 2009; 121(2): 114–118
Mira Baron

Safety Assessment Of A Proprietary Preparation Of A Novel Probiotic, Bacillus Coagulans, As A Food Ingredient
Food and Chemical Toxicology, 2009; 47: 1231–1238
J.R. Endresa,*, A. Clewella, K.A. Jadea, T. Farberb, J. Hauswirthc A.G. Schaussa